A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
326actual
Sites
93
Countries
Argentina, Australia, China +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-08 | actual | When the study began enrolling |
| Primary completion | 2025-11-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-03 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Uncontrolled Hypertension
- Resistant Hypertension
Interventions
- Drug: Baxdrostat — also filed as CIN-107
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in seated SBP at Week 12
measured At Week 12
Publications
- PMID 40850955 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed